Literature DB >> 21267694

Mechanisms of estrogen receptor-α upregulation in breast cancers.

Yasuo Miyoshi1, Keiko Murase, Masaru Saito, Michiko Imamura, Koushi Oh.   

Abstract

The most critical step for initiation and progression of estrogen receptor-α (ERα)-positive breast cancers is thought to be upregulation of ERα expression. There are several factors involved in this mechanism, i.e., increased promoter activity of the ERα gene (ESR1) at the transcriptional level, ESR1 gene amplification, and diminished degradation of ERα protein through ubiquitination and proteasomal pathways. Mediating these factors, ERα protein levels seem to be controlled, although the details of the mechanism remain to be clarified. In addition, for upregulation of estrogen signaling, functional changes in its action in cancer cells originating from normal epithelial cells, i.e., estrogen stimulation, which then leads to proliferation of ERα-positive cancer cells, has been recognized, but this action has not been observed in normal epithelial cells. These alterations are therefore likely to contribute to the pathogenesis of ERα-positive breast cancers.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21267694     DOI: 10.1007/s00795-010-0514-3

Source DB:  PubMed          Journal:  Med Mol Morphol        ISSN: 1860-1499            Impact factor:   2.309


  23 in total

1.  Proteasome-mediated degradation of transcriptional activators correlates with activation domain potency in vivo.

Authors:  E Molinari; M Gilman; S Natesan
Journal:  EMBO J       Date:  1999-11-15       Impact factor: 11.598

Review 2.  Estrogen signaling pathway and hormonal therapy.

Authors:  Shin-ichi Hayashi; Yuri Yamaguchi
Journal:  Breast Cancer       Date:  2008-09-26       Impact factor: 4.239

3.  Proliferation of estrogen receptor-alpha-positive mammary epithelial cells is restrained by transforming growth factor-beta1 in adult mice.

Authors:  Kenneth B R Ewan; Hellen A Oketch-Rabah; Shraddha A Ravani; G Shyamala; Harold L Moses; Mary Helen Barcellos-Hoff
Journal:  Am J Pathol       Date:  2005-08       Impact factor: 4.307

4.  Two promoters in expression of estrogen receptor messenger RNA in human breast cancer.

Authors:  S Hayashi; K Imai; K Suga; T Kurihara; Y Higashi; K Nakachi
Journal:  Carcinogenesis       Date:  1997-03       Impact factor: 4.944

5.  The 26S proteasome is required for estrogen receptor-alpha and coactivator turnover and for efficient estrogen receptor-alpha transactivation.

Authors:  D M Lonard; Z Nawaz; C L Smith; B W O'Malley
Journal:  Mol Cell       Date:  2000-06       Impact factor: 17.970

6.  Estrogen insensitivity in a model of estrogen receptor positive breast cancer lymph node metastasis.

Authors:  Joshua Chuck Harrell; Wendy W Dye; Djuana M E Harvell; Mauricio Pinto; Paul Jedlicka; Carol A Sartorius; Kathryn B Horwitz
Journal:  Cancer Res       Date:  2007-11-01       Impact factor: 12.701

7.  Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer.

Authors:  Frederik Holst; Phillip R Stahl; Christian Ruiz; Olaf Hellwinkel; Zeenath Jehan; Marc Wendland; Annette Lebeau; Luigi Terracciano; Khawla Al-Kuraya; Fritz Jänicke; Guido Sauter; Ronald Simon
Journal:  Nat Genet       Date:  2007-04-08       Impact factor: 38.330

8.  Differential regulation of estrogen receptor alpha turnover and transactivation by Mdm2 and stress-inducing agents.

Authors:  Vanessa Duong; Nathalie Boulle; Sylvain Daujat; Jérôme Chauvet; Sandrine Bonnet; Henry Neel; Vincent Cavaillès
Journal:  Cancer Res       Date:  2007-06-01       Impact factor: 12.701

9.  Autocrine regulation of cell proliferation by estrogen receptor-alpha in estrogen receptor-alpha-positive breast cancer cell lines.

Authors:  Huining Tan; Yili Zhong; Zhongzong Pan
Journal:  BMC Cancer       Date:  2009-01-26       Impact factor: 4.430

10.  Measurement of oestrogen receptor mRNA levels in human breast tumours.

Authors:  J A Henry; S Nicholson; J R Farndon; B R Westley; F E May
Journal:  Br J Cancer       Date:  1988-11       Impact factor: 7.640

View more
  19 in total

1.  ZBTB7A governs estrogen receptor alpha expression in breast cancer.

Authors:  Mary Ellen Molloy; Monika Lewinska; Amanda K Williamson; Thanh Thao Nguyen; Gamze Kuser-Abali; Lu Gong; Jiawei Yan; John B Little; Pier Paolo Pandolfi; Zhi-Min Yuan
Journal:  J Mol Cell Biol       Date:  2018-08-01       Impact factor: 6.216

Review 2.  Neuroprotective effects of estrogens and androgens in CNS inflammation and neurodegeneration.

Authors:  Rory D Spence; Rhonda R Voskuhl
Journal:  Front Neuroendocrinol       Date:  2011-12-24       Impact factor: 8.606

3.  17β-estradiol regulates the malignancy of cancer stem-like cells derived from the MCF7 cell line partially through Sox2.

Authors:  Lian Guo; Feng Li; Mengyuan Wang; Yue Xu; Bangqiong Wang; Dongchuan Ran; Xianxiang Zhang
Journal:  Oncol Lett       Date:  2018-01-15       Impact factor: 2.967

4.  S100A8/A9 is associated with estrogen receptor loss in breast cancer.

Authors:  Y I Bao; Antao Wang; Juanfen Mo
Journal:  Oncol Lett       Date:  2016-01-20       Impact factor: 2.967

5.  PRISM offers a comprehensive genomic approach to transcription factor function prediction.

Authors:  Aaron M Wenger; Shoa L Clarke; Harendra Guturu; Jenny Chen; Bruce T Schaar; Cory Y McLean; Gill Bejerano
Journal:  Genome Res       Date:  2013-02-04       Impact factor: 9.043

6.  Induction of the CLOCK gene by E2-ERα signaling promotes the proliferation of breast cancer cells.

Authors:  Liyun Xiao; Alan K Chang; Ming-Xi Zang; Hailian Bi; Shujing Li; Miao Wang; Xinrong Xing; Huijian Wu
Journal:  PLoS One       Date:  2014-05-02       Impact factor: 3.240

7.  OTUD7B stabilizes estrogen receptor α and promotes breast cancer cell proliferation.

Authors:  Jianing Tang; Zeyu Wu; Zelin Tian; Wei Chen; Gaosong Wu
Journal:  Cell Death Dis       Date:  2021-05-25       Impact factor: 8.469

8.  Protein kinase D1 regulates ERα-positive breast cancer cell growth response to 17β-estradiol and contributes to poor prognosis in patients.

Authors:  Manale Karam; Ivan Bièche; Christine Legay; Sophie Vacher; Christian Auclair; Jean-Marc Ricort
Journal:  J Cell Mol Med       Date:  2014-10-07       Impact factor: 5.310

9.  Emodin and Aloe-Emodin Suppress Breast Cancer Cell Proliferation through ER α Inhibition.

Authors:  Pao-Hsuan Huang; Chih-Yang Huang; Mei-Chih Chen; Yueh-Tsung Lee; Chia-Herng Yue; Hsin-Yi Wang; Ho Lin
Journal:  Evid Based Complement Alternat Med       Date:  2013-06-24       Impact factor: 2.629

10.  The wedelolactone derivative inhibits estrogen receptor-mediated breast, endometrial, and ovarian cancer cells growth.

Authors:  Defeng Xu; Tzu-Hua Lin; Chiuan-Ren Yeh; Max A Cheng; Lu-Min Chen; Chawnshang Chang; Shuyuan Yeh
Journal:  Biomed Res Int       Date:  2014-08-13       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.